Android app on Google Play

Boston Scientific (BSX) 'Surprises' ACC with WATCHMAN Presentation Plans

March 5, 2013 12:34 PM EST Send to a Friend
Boston Scientific (NYSE: BSX) said on Monday that is planned to present "acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy" at the 62nd Annual Scientific Session of the American College of Cardiology this weekend, a more limited release of data than was expected.

According to reports out Tuesday, the data is currently under review ahead of the presentation this weekend. One spokesperson for the ACoC said, "The release yesterday surprised us. We are investigating with them how much they will present."

WATCHMAN is used to seal off a reservoir in the upper chamber of the heart, where blood could form pools, potentially leading to clots. The study is being conducted to see whether WATCHMAN would be able to prevent strokes.

Shares of Boston Scientific are down 0.5 percent on the session.




You May Also Be Interested In


Related Categories

FDA, Insiders' Blog

Add Your Comment